drugset / Trial / NCT01868906

Summary

The aim of this study is to assess, with 18F-FMISO PET, hypoxia in high grade gliomas and changes by spinal cord stimulation in a subset of patients. Additionally, the potential correlation with pathological, imaging and clinical parameters will be analyzed.

Timeline

Start
2013-06
Primary completion
2017-09-17
Completion
2017-09-17

Outcome

Outcome not reported

Stopped: “Isotope (FMISO) production is no longer available in our country.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluoromisonidazole Diagnostic / imaging agent — —
Background Temozolomide Small molecule — —

Indications